2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

Pfizer is making another large oncology bet, this time through a broad collaboration with Innovent Biologics that could be worth up to $10.5 billion. The agreement includes $650 million upfront and covers 12 early stage cancer programs, including antibody drug conjugates and multispecific antibodies. That mix is important because both categories are becoming central to how large drugmakers are trying to rebuild oncology pipelines. Antibody drug conjugates in particular have moved from a niche modality into a mainstream oncology strategy, with recent clinical reviews describing them as one of the more active areas in solid tumor drug development. Pfizer will rely on Innovent to move the programs through phase 1, after which Pfizer will take over global development for many of the assets. The structure gives Innovent global reach while giving Pfizer access to a broader oncology pipeline without waiting for internal discovery programs to mature. It also reflects a larger pattern in pharma dealmaking, with multinational companies increasingly turning to China based biotechs for assets that may be developed globally rather than only regionally. The size of the deal makes the signal hard to miss. For physicians, the immediate clinical impact is still years away, but the broader point is that the next wave of oncology trials may increasingly come from cross border partnerships like this one, as detailed in Reuters coverage of the agreement and a recent Lancet review of antibody drug conjugates.

Guselkumab (Tremfya) gains expanded psoriatic arthritis label with joint damage data

Johnson & Johnson has secured an FDA label expansion for guselkumab (Tremfya) in adults with active psoriatic arthritis, adding evidence that the drug can inhibit progression of structural joint damage. That is a meaningful update because psoriatic arthritis is not just a symptom control disease. For many patients, the long term concern is preventing irreversible erosive damage while also improving pain, stiffness, skin disease, and function. The label expansion is supported by the phase 3b APEX trial, which enrolled biologic naive adults with active and erosive psoriatic arthritis. At week 24, American College of Rheumatology 20% response rates were 66.6% with guselkumab every 4 weeks and 68.3% with guselkumab every 8 weeks, compared with 47.0% with placebo. Radiographic progression was also lower with guselkumab, with least squares mean changes in Psoriatic Arthritis modified van der Heijde Sharp score of 0.55 and 0.54 versus 1.35 with placebo. The safety findings were reassuring in the trial, with no new safety signals reported through week 24. Clinically, this gives rheumatologists a stronger disease modification argument for guselkumab in a crowded biologic market. Commercially, it helps Johnson & Johnson differentiate an interleukin 23 inhibitor in a space where physicians are looking for more than skin clearance alone. The update is outlined in Johnson & Johnson’s FDA announcement, with the clinical data published in Annals of the Rheumatic Diseases.

Venetoclax (Venclyxto) expands options in first line chronic lymphocytic leukemia

Recently, AbbVie received European Commission authorization for an expanded venetoclax (Venclyxto) label in previously untreated chronic lymphocytic leukemia, giving clinicians additional chemotherapy free combination options. The updated European indication includes venetoclax with acalabrutinib, with or without obinutuzumab, as well as venetoclax with ibrutinib and the already established obinutuzumab regimen. This is very much in line with where chronic lymphocytic leukemia care has been heading. For many patients, the field has moved away from traditional chemoimmunotherapy and toward oral targeted regimens that can be tailored by comorbidity, risk profile, and patient preference. The AMPLIFY phase 3 trial is a key part of the story, showing that fixed duration acalabrutinib and venetoclax based regimens significantly prolonged progression free survival compared with chemoimmunotherapy in fit, previously untreated patients. Three year progression free survival was 76.5% with acalabrutinib plus venetoclax and 83.1% with acalabrutinib, venetoclax, and obinutuzumab, compared with 66.5% with chemoimmunotherapy. For physicians, the practical question is becoming less whether targeted therapy belongs in first line chronic lymphocytic leukemia and more how to choose among fixed duration combinations, continuous Bruton tyrosine kinase inhibition, and patient specific safety considerations. For AbbVie, the label expansion helps keep venetoclax central to that discussion as competitors continue to build around Bruton tyrosine kinase inhibitors. The regulatory update is described in AbbVie’s announcement, with the AMPLIFY results published in The New England Journal of Medicine.

Seladelpar (Livdelzi) data support earlier ambition in primary biliary cholangitis

Gilead’s seladelpar (Livdelzi) has delivered positive phase 3 IDEAL data that could broaden how the drug is used in primary biliary cholangitis. The trial focused on patients who still had alkaline phosphatase above normal but below 1.67 times the upper limit of normal despite ursodeoxycholic acid, or who could not tolerate it. That is a clinically interesting group because these patients may not look as severe as traditional trial populations, but persistent alkaline phosphatase elevation still matters for long term risk. IDEAL showed statistically significant composite alkaline phosphatase normalization at 52 weeks, which supports the idea that treatment goals in primary biliary cholangitis may be shifting toward earlier and deeper biochemical control. The broader evidence base for seladelpar was strengthened by the phase 3 RESPONSE trial, where 61.7% of patients receiving seladelpar had a biochemical response compared with 20.0% receiving placebo. Alkaline phosphatase normalization occurred in 25.0% of patients on seladelpar and in none of the patients on placebo. For hepatologists, the important point is not just that another second line option exists, but that the bar for response may be moving beyond partial improvement. For Gilead, the data also strengthen the rare liver disease portfolio it built through the CymaBay acquisition. The new IDEAL results are summarized in Gilead’s phase 3 update, with the pivotal RESPONSE data published in The New England Journal of Medicine.